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Background-—The prevalence estimates of statin eligibility among Hispanic/Latinos living in the United States under the new 2013
American College of Cardiology/American Heart Association (ACC/AHA) cholesterol treatment guidelines are not known.
Methods and Results-—We estimated prevalence of statin eligibility under 2013 ACC/AHA and 3rd National Cholesterol Education
Program Adult Treatment Panel (NCEP/ATP III) guidelines among Hispanic Community Health Study/Study of Latinos (n=16 415;
mean age 41 years, 40% males) by using sampling weights calibrated to the 2010 US census. We examined the characteristics of
Hispanic/Latinos treated and not treated with statins under both guidelines. We also redetermined the statin-therapy eligibility by
using black risk estimates for Dominicans, Cubans, Puerto Ricans, and Central Americans. Compared with NCEP/ATP III guidelines,
statin eligibility increased from 15.9% (95% CI 15.0–16.7%) to 26.9% (95% CI 25.7–28.0%) under the 2013 ACC/AHA guidelines.
This was mainly driven by the ≥7.5% atherosclerotic cardiovascular disease risk criteria (prevalence 13.9% [95% CI 13.0–14.7%]).
Of the participants eligible for statin eligibility under NCEP/ATP III and ACC/AHA guidelines, only 28.2% (95% CI 26.3–30.0%) and
20.6% (95% CI 19.4–21.9%) were taking statins, respectively. Statin-eligible participants who were not taking statins had a higher
prevalence of cardiovascular risk factors compared with statin-eligible participants who were taking statins. There was no
significant increase in statin eligibility when atherosclerotic cardiovascular disease risk was calculated by using black estimates
instead of recommended white estimates (increase by 1.4%, P=0.12) for Hispanic/Latinos.
Conclusions-—The eligibility of statin therapy increased consistently across all Hispanic/Latinos subgroups under the
2013 ACC/AHA guidelines and therefore will potentially increase the number of undertreated Hispanic/Latinos in the United
States. ( J Am Heart Assoc. 2017;6:e005045. DOI: 10.1161/JAHA.116.005045.)
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I n 2013, American College of Cardiology/American HeartAssociation (ACC/AHA) cholesterol treatment guidelines
based on high-quality evidence were published.1 These
guidelines replaced the previous cholesterol treatment
guidelines: the third report of the national cholesterol
education program/adult cholesterol treatment panel III
(NCEP/ATP III).2 Applying data from the National Health and
Nutrition Examination Surveys, researchers suggested that
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ORIGINAL RESEARCH
the new 2013 ACC/AHA guidelines for the management of
cholesterol could potentially increase the number of statin-
therapy eligible US adults by 12.8 million.3 However, this
study did not include several of the Hispanic/Latino subpop-
ulations and only included Mexican Hispanics. In addition,
current cholesterol treatment guidelines were based on either
non-Hispanic white and/or black populations and did not take
into account Hispanics/Latinos.
Hispanics/Latinos currently constitute 18% of the US
population, making them the largest ethnic minority. It is
important to study the statin eligibility to direct healthcare
needs for primary prevention of cardiovascular disease in this
ethnic group. The current guidelines provided an atheroscle-
rotic cardiovascular disease (ASCVD) calculator to estimate 10-
year ASCVD risk. This calculator uses the same estimates for
Hispanic/Latinos as that of whites. However, several of the
Hispanics/Latinos share their ancestry with African ancestry,
particularly Caribbean-Hispanics (Cubans, Dominican, and
Puerto Rican descent) and Central Americans.4–7 It is likely
that not recognizing the African ancestry in certain Hispanic
groups could underestimate ASCVD risk. It is important to
address these knowledge gaps as it would potentially provide
data of public health importance that could be utilized to
address the current disparities in primary prevention of ASCVD.
Therefore, we determined the prevalence estimates from the
Hispanic Community Health Study/Study of Latinos eligible for
cholesterol treatment under the new 2013 ACC/AHA guideli-
nes and previous NCEP/ATP III guidelines. We further examined
the prevalence of US Hispanics/Latinos who are eligible for
statin therapy but are currently not on statin therapy.
Methods
Study Design and Population
The Hispanic community health study/study of Latinos (HCHS/
SOL) is a community-based study of 16 415 Hispanic/Latino
adults aged 18 to 74 years at recruitment, recruited from 4 US
metropolitan areas (Bronx, NY; Chicago, IL; Miami, FL; and San
Diego, CA).8 Participants were recruited by using a 2-stage
probability sample design, as described previously.9 A compre-
hensive battery of interviews relating to personal and family
characteristics, health status and behaviors, and a clinical
assessment with blood draws were conducted at an in-person
baseline clinic visit during 2008 to 2011. The study was
approved by the institutional review boards at all participating
institutions, and all participants gave written informed consent.
Risk Factor Assessment
Participants were asked to fast and refrain from smoking
on the morning before the HCHS/SOL baseline clinic visit.
Following a 5-minute rest period, 3 seated blood pressure
measurements were obtained with an automatic sphygmo-
manometer, which were averaged. Total cholesterol, high-
density lipoprotein cholesterol, low-density lipoprotein
cholesterol, triglycerides, and fasting glucose were mea-
sured using standardized methods described previously.10,11
Height, waist circumference, and hip circumference were
measured to the nearest centimeter and weight to the
nearest 0.1 kg. BMI was calculated as weight in kilograms
divided by height in meters squared. Interviewer-adminis-
tered questionnaires were used to collect information on
age, sex, annual household income, educational attainment,
Hispanic/Latino background, employment status, health
insurance status, and history of smoking. Diabetes mellitus
was defined as fasting glucose ≥126 mg/dL, 2-hour–
postload plasma glucose ≥200 mg/dL, hemoglobin A1c
≥6.5%, use of diabetes medications, or self-reported history
of diabetes mellitus. Participants were instructed to bring
all prescription and nonprescription medications taken in
the past 4 weeks; medication preparations, concentrations,
and units were coded for analysis. We defined statin
medication use as the use of at least 1 statin (3-hydroxy-3-
methyglutaryl coenzyme A reductase inhibitors) medication.
Cholesterol Treatment Guidelines and Statin
Eligibility
Statin eligibility was defined by using the following NCEP/ATP
III updated guidelines12 and ACC/AHA guidelines. As per
2004 NCEP/ATP III guidelines, statin-eligible participants
included participants with (1) prevalent coronary heart
disease, defined as myocardial infarction, coronary bypass
surgery, balloon angioplasty, or stent placement in coronary
arteries, and low-density lipoprotein (LDL) cholesterol of 100
or higher; (2) LDL cholesterol of 190 mg/dL or higher; (3)
diabetes mellitus and LDL cholesterol of 100 or higher; (4)
combination of calculated 10-year coronary heart disease
Risk (using the Framingham risk calculator) and LDL choles-
terol levels: (1) risk of 20% or greater and LDL cholesterol of
100 mg/dL or higher; (2) risk of 10% to 20% and LDL
cholesterol of 130 mg/dL or higher with 2 or more risk
factors (smoking, hypertension, high-density lipoprotein
cholesterol less than 40 mg/dL, myocardial infarction or
angina in first-degree relative before age 50, and age
[45 years or older for men, 55 years or older for women]);
(3) risk of less than 10% and LDL cholesterol of 160 mg or
higher with 2 or more risk factors.
By 2013 ACC/AHA class I guidelines,13 statin-eligible
participants included the following: (1) prevalent cardiovas-
cular disease, defined as coronary heart disease, angina, or
stroke; (2) LDL cholesterol of 190 mg/dL or higher; (3)
diabetes mellitus and LDL cholesterol of 70 mg/dL or
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higher; and (4) 10-year cardiovascular disease risk of 7.5% or
greater, based on the pooled cohort equations and LDL
cholesterol of 70 or higher.14
Statistical Analysis
We chose a probability sampling strategy with face-to-face
recruitment. Geographic clusters were stratified by the
proportion of the population found to be Hispanic/Latino in
the 2000 decennial census, and clusters in the “high
concentration” stratum were selected at a higher rate than
clusters in the “low concentration” stratum at the first stage
of sample selection. An optimal delineation point between
high and low concentration was determined for each field
center using Cochran’s cumulative √f rule.15 Furthermore, we
also used Hispanic/Latino surnames to identify home
addresses in these geographic areas and were oversamples
compared to the home addresses without Hispanic/Latino
surnames. We used SAS SURVEY command to calculate the
prevalence estimates by using sampling weights, which took
into account nonresponse and oversampling of specific
population subgroups to provide weighted frequencies of
descriptive variables and population estimates of statin-
therapy eligibility. Weights were calibrated to 2010 US
census characteristics by age, sex, and Hispanic/Latino
background in each field center’s target population, in
accordance with the procedures commonly used in popula-
tion-based studies.9 Continuous variables were compared
using regression analysis and categorical variables were
compared using Rao–Scott v2 test. We also classified
prevalence that were statin-therapy eligible under previous
versus newer guidelines. Under the new guidelines, statin
eligibility falls into 3 criteria: (1) individuals with history of
clinical cardiovascular disease; (2) those with LDL-C
≥190 mg/dL; (3) those without known ASCVD with LDL-C
between 70 and 189 mg/dL but with ≥7.5% 10-year ASCVD
risk; and (4) those with diabetes mellitus and LDL-C
≥70 mg/dL. The new Pooled Cohort Risk Assessment
calculator was used to assess ASCVD risk using white
estimates for Hispanics.14
We then identified individuals who were not treated
(undertreatment) by statin therapy but were classified as
eligible for statin therapy. We defined statin-therapy
undertreatment as the prevalence eligible for statin therapy
under cholesterol treatment guideline but were not on statin.
We then examined prevalence of various subgroups that
were statin eligible under current and previous guidelines to
show disparities and characteristics of these individuals.
Race factors into ASCVD risk prediction in the new ACC/
AHA guidelines, with recommendations to assume white risk
estimates in all Hispanics. Since certain Hispanic groups
have more African ancestry, the current guidelines fail to
consider the complexity of the Hispanic/Latino population.
Thus, race was treated separately in sensitivity analysis. All
analyses were weighted to adjust for sampling probability
and nonresponse, to make the estimates applicable to the
target population from which the HCHS/SOL sample was
drawn in accordance with guidelines suggested by the
HCHS/SOL Steering and Data Analysis Committee. A P value
of <0.05 was considered significant. All analyses were
performed using SAS v. 9.3 (Cary, NC).
Results
Participant Characteristics
Descriptive characteristics are shown in Table 1. Hispanics/
Latinos statin-therapy eligible by ACC/AHA guidelines were
more often older, more males, and had higher systolic blood
pressure and total cholesterol than participants eligible by
NCEP/ATP III guidelines. On the other hand, the prevalence of
obesity and antihypertensive medication use was lower for
statin-eligible participants by ACC/AHA guidelines than
NCEP/ATP III guidelines.
Application of 2013 ACC/AHA Cholesterol
Treatment Guidelines to the Cohort
Figure shows the breakdown of study participants by
cholesterol treatment guidelines. Out of 16 415 participants,
4160 (26.9%; 95% CI 25.7–28.0%) were statin eligible under
the 2013 ACC/AHA guidelines while 2609 (15.9%; 95% CI
15.0–16.7%) were statin eligible under the NCEP/ATP III
guidelines. This eligibility was based on prior history of ASCVD
in 771 (4.7%; 95% CI 4.2–5.2%), LDL ≥190 mg/dL in 640
(3.9%; 95% CI 3.5–5.3%), history of diabetes mellitus in 2101
(12.8%; 95% CI 12.0–13.5%), and LDL ≥70 mg/dL with 10-
year ASCVD risk of ≥7.5% in 2281 (13.9%; 95% CI 13.0–
14.7%) (Table 2). The overall most common indication for
statin eligibility among all Hispanics/Latinos subgroups was
having ASCVD risk of ≥7.5%. When stratified by age and sex,
Puerto Rican females aged 18 to 64 years had the highest
prevalence of statin-eligible participants by 10-year ASCVD
risk of ≥7.5% criteria (v2 statistic <0.05) than other subgroups
(Table S1).
Increase in Eligibility for Statin Therapy
There was an increase in eligibility for statin therapy under the
ACC/AHA guidelines across all Hispanic/Latino subgroups as
shown in Table 3. The increase in eligibility was mainly driven
by ASCVD risk score. There was an absolute increase by
11.0% (69.1% relative increase). Particularly, the subgroups
aged >65 years and males had the highest increase in statin
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eligibility under the ACC/AHA guidelines: an absolute
increase by 45.6% (114.9% relative increase) and 14.7%
(98.6% relative increase), respectively. Among the Hispanic/
Latino subgroups, in unadjusted analysis, Cubans and South
Americans had the highest increase in statin eligibility
(Table 3). The increase in eligibility was more pronounced in
>65-year-old individuals and males (P<0.05). The age- and
sex-stratified analyses shown in Table S2 also demonstrated a
consistent pattern of increase in prevalence of statin therapy
among statin-eligible participants. In age- and sex-adjusted
analyses, the South American subgroup had the least
prevalence of statin-eligible participants by both NCEP/ATP
III guidelines and ACC/AHA guidelines, while the Puerto Rican
subgroup had the highest prevalence of statin-eligible partic-
ipants by both guidelines (Table S3).
Statin Treatment Rates of Hispanics/Latinos
Under 2013 ACC/AHA and 2004 NCEP/ATP III
Guidelines
Among Hispanics/Latinos, prevalence of statin use was 7.9%
(95% CI 7.2–8.6%). Of the participants who were statin
eligible, only about one third and one fifth of the participants
were taking statins under NCEP/ATP III guidelines (28.2%
[95% CI 26.3–30.0%]) and ACC/AHA guidelines (20.6% [95%
CI 19.4–21.9%]), respectively (P for difference <0.0001).
Table 1. Prevalence Estimates and 95% CI by Category of ATP III and ACC/AHA Cholesterol Guidelines for Participants in the
HCHS/SOL
Characteristic All Cohort
Statin Eligible by
ATP III Guidelines
Statin Eligible by
ACC/AHA Guidelines
Newly Eligible for Statin by
ACC/AHA Guidelines
Age, y 41.0 (0.3) 52.9 (0.4) 54.3 (0.4) 55.3 (0.5)
Male 47.9 (46.8, 48.9) 45.1 (42.6, 47.7) 52.8 (50.8, 54.8) 61.7 (58.7, 64.7)
Females 54.4 (51.1, 53.2) 54.8 (52.3, 57.4) 47.2 (45.2, 49.2) 38.3 (35.3, 41.4)
Hypertension 21.8 (20.6, 22.9) 51.7 (49.0, 54.2) 50.9 (48.6, 53.3) 48.7 (45.4, 52.0)
Smoking status
Never 61.3 (60.0, 62.5) 56.2 (52.6, 58.7) 49.2 (47.1, 51.3) 40.9 (37.6, 44.1)
Former 17.4 (16.5, 18.2) 24.8 (22.6, 26.9) 24.5 (22.7, 26.2) 24.1 (21.3, 26.9)
Current 21.4 (20.3, 22.5) 19.1 (16.9, 21.3) 26.3 (24.2, 28.4) 35.0 (31.9, 38.2)
Health insurance 50.5 (48.7, 52.4) 59.4 (56.7, 62.2) 59.9 (57.6, 62.2) 59.6 (56.2, 63.0)
Education
Lower than high school 32.5 (31.1, 33.9) 43.5 (40.9, 46.0) 42.6 (40.4, 44.7) 40.8 (37.7, 43.9)
High school or equivalent 28.4 (27.3, 29.5) 23.9 (21.6, 26.3) 23.0 (21.2, 24.8) 22.0 (19.4, 24.6)
Higher than high school 39.1 (37.5, 40.7) 32.6 (30.0, 35.1) 34.4 (32.2, 36.7) 37.2 (34.0, 40.4)
Income ≥$40 000/y 20.4 (18.5, 22.4) 15.7 (13.3, 18.0) 16.2 (14.3, 18.2) 16.8 (14.0, 19.7)
Mod/high physical activity 44.5 (43.2, 45.8) 32.5 (29.7, 35.3) 35.3 (33.0, 37.6) 38.9 (35.4, 42.2)
Antihypertensive use 12.8 (12.0, 13.7) 39.4 (36.9, 42.0) 33.1 (31.0, 35.2) 25.8 (23.2, 28.4)
Systolic blood pressure, mm Hg 119.9 (0.2) 128.0 (0.5) 130.9 (0.4) 133.0 (0.6)
Obese (BMI ≥30 kg/m2) 39.6 (38.2, 40.9) 55.1 (52.7, 57.6) 48.1 (46.1, 50.2) 39.8 (36.6, 43.1)
Total cholesterol, mg/dL 194.3 (0.6) 210.6 (1.4) 214.6 (1.1) 218.3 (1.6)
High-density lipoprotein, mg/dL 48.5 (0.2) 46.6 (0.3) 47.2 (0.3) 47.4 (0.4)
Hispanic subgroups
Dominican 10.4 (8.9, 11.8) 14.4 (12.8, 16.0) 23.3 (21.1, 25.5) 11.9 (9.8, 12.2)
Central American 7.7 (6.6, 8.8) 14.6 (13.2, 16.0) 23.5 (21.5, 25.6) 10.8 (9.6, 12.1)
Cuban 20.9 (17.5, 24.3) 17.1 (15.1, 19.2) 36.6 (32.7, 40.5) 21.8 (19.5, 24.1)
Mexican 39.0 (35.6, 42.3) 15.2 (14.2, 16.2) 22.3 (20.9, 23.7) 9.7 (8.8, 10.5)
Puerto Rican 16.9 (15.2, 18.5) 18.8 (17.5, 20.1) 31.6 (29.7, 33.5) 15.3 (14.0, 16.5)
South American 5.2 (4.5, 5.8) 10.6 (9.3, 11.9) 21.5 (19.5, 23.5) 12.2 (10.8, 13.6)
Continuous variables are expressed as mean (standard error) and categorical as numbers (percentage). ACC/AHA indicates American College of Cardiology/American Heart Association;
ATP III, 3rd National Cholesterol Education Program Adult Treatment Panel; HCHS/SOL, Hispanic Community Health Study/Study of Latinos.
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Figure S1 shows prevalence of statin therapy for age, sex, and
Hispanic/Latino subgroups under both treatment guidelines.
This figure shows that younger participants, males, and all
Hispanic/Latino subgroups except Puerto Ricans were
undertreated by statins. We observed that among those
who were statin eligible under the ACC/AHA guidelines, those
not on statin therapy were significantly younger and more
likely to be males, smokers, and hypertensives. They were
also more likely to have no medical insurance and be lower
income (Table 4).
Accounting for African Ancestry of Dominicans,
Puerto Ricans, Dominicans, and Central
Americans for Calculation of 10-Year ASCVD Risk
When we used the white coefficient to calculate 10-year
ASCVD risk for all Hispanics/Latinos subgroups, about one
fourth of the participants were statin eligible (26.9% [95% CI
25.8–28.0%]) under ACC/AHA guidelines. When we used
black coefficient to estimate ASCVD risk for Dominicans,
Puerto Ricans, and Central Americans, 28.2% (95% CI 27.0–
29.4%) were statin eligible, which was a 1.3% absolute
increase in statin eligibility while 0.40% (95% CI 0.29–0.53%)
became ineligible.
Discussion
In this large population-based sample of Hispanics/Latinos
living in the United States, we observed that a higher
number of Hispanics/Latinos will be eligible for statin
therapy under the new 2013 ACC/AHA guidelines. The
increase in eligibility was found across several demographic
subgroups but was particularly higher among males, middle
aged (45–64 years) individuals, and among certain Hispanic
Figure. Eligibility for statin therapy. ACC/AHA indicates American College of Cardiology/American Heart Association; CVD, cardiovascular disease;
DM, diabetes mellitus; LDL, low-density lipoprotein; NCEP/ATP III, 3rd National Cholesterol Education Program Adult Treatment Panel; PCE, pooled
cohort equation.
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background groups (Dominicans, Puerto Ricans, and Central
Americans). We also found that only one third and one fifth
of statin-eligible Hispanics/Latinos under NCEP/ATP III
guidelines and 2013 ACC/AHA guidelines, respectively,
were taking statins. In addition, we found that changing the
estimates for 10-year ASCVD risk for the Hispanic/Latino
subgroups for Dominicans, Puerto Ricans, and Central
Americans did not significantly increase statin eligibility.
To our knowledge, this is the first population-based study of
Hispanics/Latinos living in the United States that has provided
prevalence estimates of statin eligibility under 2013 ACC/AHA
cholesterol and 2004 NCEP/ATP III cholesterol treatment
guidelines. The findings of this study are consistent with other
studies showing increase in statin eligibility among whites,16
Europeans,17 and Koreans, Mexican majority Hispanics, and
Chileans.18–21 The newer guidelines have expanded the
Table 2. Prevalence Estimates and 95% CI for Statin Therapy by 2013 ACC/AHA Cholesterol Treatment Class I Guideline-Based
Categories
History of
ASCVD P Value LDL ≥190 mg/dL P Value Diabetes Mellitus P Value
≥7.5% of ASCVD Risk
and LDL ≥70 mg/dL P Value
All 4.7 (4.2, 5.2) 3.9 (3.5, 4.3) 12.8 (12.0, 13.5) 13.9 (13.0, 14.7)
Age 18 to 44, y 2.4 (2.1, 2.7) <0.0001 2.2 (2.0, 2.5) 5.0 (4.7, 5.4) <0.0001 1.5 (1.3, 1.7) <0.0001
Age 45 to 64, y 7.0 (6.4, 7.6) 6.7 (6.1, 7.3) <0.0001 20.7 (19.6, 21.7) 21.8 (20.6, 23.0)
Age >65, y 12.6 (11.2, 14.1) 5.2 (4.4, 6.1) 37.4 (34.5, 40.4) 71.0 (66.3, 75.7)
Female 2.0 (1.6, 2.3) 0.0001 2.0 (1.7, 2.2) 0.48 7.2 (6.6, 7.8) 0.008 5.6 (5.1, 6.1) <0.0001
Male 2.8 (2.3, 3.2) 1.9 (1.6 2.2) 5.6 (5.1, 6.0) 8.3 (7.6, 8.9)
Dominican 4.2 (3.6, 4.9) <0.0001 3.8 (3.2, 4.4) 11.4 (10.1, 12.8) <0.0001 10.4 (9.0, 11.7) <0.0001
Central American 3.4 (2.7, 4.0) 4.0 (3.4, 4.7) 11.6 (10.5, 12.8) 11.5 (10.4, 12.7)
Cuban 5.3 (4.6, 6.1) 5.7 (5.0, 6.5) 13.9 (12.2, 15.6) 23.6 (21.2, 26.1)
Mexican 3.4 (3.0, 3.9) 3.4 (3.0, 3.9) 0.0002 11.9 (11.1, 12.7) 9.7 (8.9, 10.4)
Puerto Rican 7.5 (6.7, 8.3) 3.1 (2.6, 3.6) 15.8 (14.7, 16.9) 16.9 (15.5, 18.2)
South American 3.5 (2.8, 4.2) 4.2 (3.4, 4.9) 8.3 (7.2, 9.4) 12.3 (10.8, 13.7)
The percentages are related to the total number of individuals eligible for statin therapy by ACC/AHA class I guidelines in each subgroup. ACC/AHA indicates American College of
Cardiology/American Heart Association; ASCVD, atherosclerotic cardiovascular disease; LDL, low-density lipoprotein.
Table 3. Prevalence Estimates and 95% CI of Statin-Therapy Eligible Under Both Guidelines
2004 ATP III/NCEP 2013 ACC/AHA Newly Eligible
P Value
Absolute
Increase*
Relative
Increase†Prevalence Estimates (95% CI)
All 15.9 (15.0, 16.7) 26.9 (25.7, 28.0) 13.2 (12.4, 14.1) 11.0% 69.1%
Age 18 to 44, y 7.0 (6.7, 7.2) 10.0 (9.4, 10.5) 4.3 (3.9, 4.6) <0.0001 3.0% 42.8%
Age 45 to 64, y 25.4 (24.5, 26.3) 42.0 (39.8, 44.1) 20.4 (19.1, 21.7) 16.6% 65.3%
Age >65, y 43.4 (38.8, 47.9) 89.0 (83.5, 94.5) 49.9 (46.3, 53.4) 45.6% 114.9%
Female 16.8 (15.9, 17.7) 24.4 (23.3, 25.6) 9.7 (9.1, 10.3) <0.0001 7.6% 45.2%
Male 14.9 (14.1, 15.7) 29.6 (28.1, 31.1) 17.8 (16.7, 18.8) 14.7% 98.6%
Dominican 14.4 (12.8, 16.0) 23.4 (21.2, 25.5) 11.0 (9.8, 12.2) <0.0001 9.0% 62.5%
Central American 14.6 (6.9, 22.4) 23.6 (21.5, 25.6) 10.8 (9.6, 12.1) 9.0% 61.6%
Cuban 17.1 (15.1, 19.2) 36.6 (32.7, 40.5) 21.8 (19.5, 24.1) 19.5% 114.0%
Mexican 15.2 (14.2, 16.2) 22.3 (20.9, 23.7) 9.7 (8.8, 10.5) 7.1% 46.7%
Puerto Rican 18.8 (17.5, 20.1) 31.6 (29.7, 33.5) 15.3 (14.0, 16.5) 12.8% 68.1%
South American 10.6 (9.3, 11.9) 21.5 (19.5, 23.5) 12.2 (10.8, 13.6) 10.9% 102.8%
ACC/AHA indicates American College of Cardiology/American Heart Association; ATP III/NCEP, 3rd National Cholesterol Education Program Adult Treatment Panel.
*Absolute increase in eligibility in a subgroup=([Eligible by ACC/AHAEligible by ATP III/NCEP]/total number at risk in that subgroup)9100%.
†Relative increase in eligibility in a subgroup=([Eligible by ACC/AHAEligible by ATP III/NCEP]/Eligible by ATPIII/NCEP)9100%.
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indications for statin therapy by including ASCVD risk score and
have shown almost doubling of the statin eligibility.16–18,22 Our
study confirms a prior study where themajority of the Hispanics
were of Mexican origin. However, the study did not provide
prevalence estimates and did not represent all the subgroups of
Hispanic/Latino origin.22 An important aspect of our analysis
that sets it apart from other analyses is inclusion of younger
(<45-year-old) individuals who are included in the guidelines but
have not been studied in the European cohort. Approximately
one tenth of these individuals were eligible for statins under the
new guidelines and had significant differences among the
various Hispanic subgroups, with the Puerto Rican female
subgroup having the highest prevalence of individuals who
qualified for statin therapy. The prevalence of statin therapy
eligibility among 6 Hispanics/Latinos subgroups that this study
has provided has not been previously studied. In addition, there
was a concern that usingwhite estimates for Hispanics/Latinos
under thenewerguidelinesmightnotbeappropriate forHispanic
subgroupswith predominance of African ancestry. However, we
did not detect a significant difference in increase in prevalence
whenwhite estimateswere used for Dominicans, Puerto Ricans,
Central Americans, and Cubans.
Table 4. Prevalence Estimates (%) and 95% CI for Statin Eligible on Statins and Not on Statins Under Both Guidelines
Variables
Statin Eligible by ATP III
Guidelines on Statins
Statin Eligible by ATP III
Guidelines Not
on Statins P Value
Statin Eligible by
ACC/AHA
Guidelines on Statins
Statin Eligible by
ACC/AHA Guidelines
Not on Statins P Value
All 28.2 (26.3, 30.0) 71.8 (68.4, 75.3) 20.6 (19.4, 21.9) 79.4 (75.6, 83.1)
Age, y 59.8 (0.5) 50.5 (0.5) <0.001 61.0 (0.4) 52.7 (0.4) <0.001
Male 43.4 (38.3, 48.4) 45.2 (42.1, 48.3) 0.29 46.9 (42.3, 51.4) 54.0 (51.6, 56.2) 0.007
Female 56.6 (51.5, 61.6) 54.9 (51.8, 58.0) 53.1 (48.6, 57.7) 46.0 (43.7, 48.3)
Hypertension 77.9 (74.1, 81.7) 42.8 (39.7, 45.9) <0.001 75.7 (71.9, 79.4) 45.6 (42.8, 48.4) <0.001
Smoking status 0.03 <0.001
Never 55.9 (51.5, 60.4) 56.4 (53.2, 59.6) 53.2 (49.2, 57.3) 48.5 (46.0, 50.9)
Former 28.8 (24.7, 32.8) 23.6 (21.1, 26.0) 30.1 (26.3, 33.9) 23.1 (21.1, 25.1)
Current 15.3 (11.8, 18.9) 20.0 (17.5, 22.5) 16.7 (13.3, 20.1) 28.4 (26.1, 30.8)
Health insurance 82.3 (78.4, 86.2) 50.9 (47.9, 53.8) <0.001 85.6 (82.6, 88.6) 53.4 (50.9, 56.0) <0.001
Education 0.007 0.004
Lower than high school 14.4 (12.7, 16.1) 29.6 (27.1, 32.1) 49.6 (45.4, 53.7) 41.1 (38.6, 43.5)
High school or equivalent 5.4 (4.0, 6.8) 17.6 (15.5, 19.7) 18.4 (14.8, 21.9) 23.6 (21.5, 25.8)
Higher than high school 8.4 (6.9, 10.0) 24.4 (22.2, 26.7) 32.0 (27.4, 36.7) 35.3 (32.8, 37.7)
Income ≥$40 000/y 15.8 (11.6, 20.1) 15.1 (12.6, 17.5) 0.02 18.2 (14.0, 22.4) 15.7 (13.7, 17.8) 0.09
Moderate/high physical activity 27.9 (22.4, 33.5) 33.6 (30.2, 36.8) 0.10 26.8 (22.1, 31.6) 63.0 (60.2, 65.8) 0.001
Antihypertensive use 70.5 (66.4, 74.6) 27.3 (24.7, 29.8) <0.001 65.7 (61.6, 69.8) 24.6 (22.5, 26.7) <0.001
Systolic blood pressure, mm Hg 131.2 (0.8) 126.7 (0.6) <0.001 133.1 (0.7) 130.4 (0.5) <0.001
Obese (BMI ≥30 kg/m2) 16.4 (14.3, 18.5) 39.2 (36.7, 41.6) 0.14 10.6 (9.2, 12.1) 37.6 (35.6, 39.7) 0.10
Total cholesterol, mg/dL 185.0 (2.1) 220.3 (1.6) <0.001 193.5 (1.9) 220.3 (1.2) <0.001
High-density lipoprotein, mg/dL 47.6 (0.6) 46.3 (0.4) <0.001 48.5 (0.6) 46.8 (0.3) <0.001
Hispanic subgroups <0.001
Dominican 10.5 (7.6, 13.3) 9.2 (7.0, 11.3) 9.8 (7.3, 12.3) 8.7 (7.0, 10.3)
Central American 5.7 (3.7, 7.8) 7.8 (6.4, 9.3) 4.9 (3.3, 6.6) 7.2 (6.0, 8.5)
Cuban 23.8 (18.4, 29.1) 22.3 (18.0, 26.7) 26.2 (21.6, 30.7) 29.2 (24.6, 33.7)
Mexican 29.4 (24.5, 34.2) 40.7 (36.3, 45.0) 28.0 (23.7, 32.3) 33.2 (29.3, 37.2)
Puerto Rican 27.3 (23.3, 31.3) 27.3 (23.3, 31.3) 27.6 (23.9, 31.2) 17.3 (15.0, 19.7)
South American 3.3 (2.1, 4.5) 3.7 (2.7, 4.7) 3.6 (2.4, 4.7) 4.4 (3.5, 5.2)
ACC/AHA indicates American College of Cardiology/American Heart Association; ATP III/NCEP, 3rd National Cholesterol Education Program Adult Treatment Panel.
Continuous variables are expressed as mean (SE) and categorical as numbers (percentage). Continuous variables were compared using survey regression method and categorical variables
were compared using Rao–Scott v2 method.
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Furthermore, the ASCVD risk estimator under the current
guidelines may not hold for Hispanics the same way as they
do for other ethnicities. The current guidelines rely on
cardiovascular risk factors to assign particular 10-year ASCVD
risk. Hispanics are known to have a higher burden of
cardiovascular risk factors and thus are likely to have higher
estimates for ASCVD risk based on current guidelines;
however, there is a documented notion that despite high
cardiovascular risk factor burden, Hispanics suffer from much
lower overall and cardiovascular mortality than other race–
ethnic groups such as non-Hispanic whites and black
Americans, a phenomenon known as “Hispanic paradox” in
scientific literature.23,24 The Hispanic paradox may or may not
be applicable across all Hispanic background groups,25,26 and
future prospective data from the HCHS/SOL will help
elucidate cardiovascular risk for Hispanics. This becomes
important in the light of a recent “real-world” study that
showed that ASCVD risk by AHA/ACC guidelines might lead
to overestimation of ASCVD risk.27 Among 18 745 (6.1%)
Hispanics included in this study, the risk score overestimated
the risk of ASCVD events. Thus, our study further emphasizes
the critical need to have race/ethnic–based calibrated
scores.28
There are several implications of this study. First, this
study demonstrates and confirms findings similar to other
cohort studies in Hispanics. Secondly, it showed important
differences across several subgroups of Hispanics/Latinos.
Thirdly, the study showed gross undertreatment of US-based
Hispanics/Latinos in regard to primary prevention of cardio-
vascular disease. This level of undertreatment is likely to
increase when the indications for statin therapy are going to
increase eligible participants under the newer ACC/AHA
cholesterol treatment guidelines. We also observed gross
differences in demographics of participants already on statin
therapy compared with those not on statin therapy but who
were eligible under the new and old guidelines. These
differences will potentially inform public health policy makers
to target certain subgroups of Hispanics/Latinos to improve
primary prevention of ASCVD. Lastly, the study did not show a
significant increase in statin eligibility when black ASCVD risk
estimates were used to identify participants with greater than
7.5% 10-year risk of ASCVD, suggesting that it may be
appropriate to use any of the estimates; however, having in
mind the Hispanic paradox, the white and black estimates
might erroneously increase the statin eligibility in Hispanics/
Latinos. Hispanics/Latinos constitute the largest ethnic
minority in the United States and already suffer from
disparities in cholesterol treatment that could potentially be
increased by inaccurately estimating their ASCVD risk.
However, this does not disregard the need for clinician–
patient risk discussion. We also identified 2% to 3% of
Hispanics who became ineligible by ACC/AHA guidelines who
were eligible under NCEP/ATP III guidelines. This is an
important group to focus on, as they might still be at high risk
of cardiovascular disease and would benefit from clinician–
patient risk discussion.
There are several limitations of this analysis. First, this is a
cross-sectional analysis and does not take into account the
longitudinal changes in the risk factors that determine the
eligibility of statin use nor the pretreatment LDL cholesterol
levels among individuals who were using statins at enroll-
ment. Therefore, it is likely that some individuals might be
misclassified. Second, much of the data were self-reported,
which can be a source of recall bias. However, the risk scores
were calculated based on objective data. Third, we did not
account for treatment adherence, which in several series has
been reported to be low for statins.29–32
Currently, more than one third of the US community-
dwelling Hispanics/Latinos eligible under the new as well as
old treatment guidelines are not on statin therapy. There is a
need for Hispanics/Latinos–specific ethnic estimates for
estimating 10-year ASCVD risk. The study indicates the need
for additional resources for improving cardiovascular health
for Hispanics/Latinos.
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Table S1. Age and Sex Stratified Prevalence estimates and 95% confidence intervals for statin therapy by 2013 ACC/AHA cholesterol treatment class I guideline based 
categories  
Age categories Sex Categories Ethnic Subgroups History of ASCVD LDL ≥190 mg/dl Diabetes mellitus ≥7.5% of ASCVD risk and LDL ≥70 mg/dl 
18 – 44 Females 
Dominican 2.2 (1.2, 3.1) 1.9 (1.1, 2.7) 4.7 (3.1, 6.2) 1.3 (0.7, 1.9) 
Central American 1.3 (0.8, 1.88) 2.1 (1.3, 2.8) 5.4 (4.2, 6.5) 1.8 (0.9, 2.8) 
Cuban 1.0 (0.5, 1.6) 2.0 (1.1, 2.9) 3.0 (2.1, 3.9) 2.0 (1.3, 2.8) 
Mexican 1.6 (1.2, 2.1) 0.5 (0.4, 0.7) 5.9 (5.1, 6.7) 1.4 (0.9, 1.9) 
Puerto-Rican 3.9 (2.6, 5.1) 1.5 (0.8, 2.2) 7.1 (5.6, 8.5) 5.5 (4.1, 6.8) 
South American 1.1 (0.3, 2.0) 1.1 (0.1, 2.1) 1.0 (0.4, 1.5) 0.5 (0.0, 1.0) 
  P 0.09 0.08 0.02 0.0002 
18 – 44 Males 
Dominican 1.6 (0.7, 2.5) 1.8 (1.0, 2.6) 5.3 (3.5, 7.2) 0.3 (0.0, 0.5) 
Central American 2.0 (1.2, 2.8) 3.0 (2.1, 4.0) 2.2 (1.4, 3.0) 0.5 (0.2, 0.9) 
Cuban 2.1 (1.1, 3.0) 4.2 (2.9, 5.6) 2.4 (1.6, 3.3) 1.7 (1.0, 2.4) 
Mexican 2.7 (1.8, 3.6) 4.0 (3.0, 4.9) 6.4 (5.4, 7.4) 1.0 (0.7, 1.3) 
Puerto-Rican 4.8 (3.4, 6.3) 2.8 (1.6, 3.9) 4.6 (3.4, 5.7) 0.8 (0.4, 1.3) 
South American 1.3 (0.5, 2.1) 2.2 (1.2, 3.1) 1.8 (0.8, 2.7) 0.6 (0.0, 1.1) 
  P 0.19 0.73 0.004 0.36 
45 – 64 Females 
Dominican 5.5 (4.3, 6.8) 8.7 (6.6, 10.7) 18.8 (16.0, 21.5) 7.0 (5.6, 8.3) 
Central American 2.4 (1.8, 3.1) 6.6 (5.0, 8.2) 20.3 (17.5, 23.2) 11.0 (8.8, 13.2) 
Cuban 3.8 (2.8, 4.7) 10.0 (8.3, 11.7) 17.8 (15.3, 20.4) 13.4 (11.5, 15.4) 
Mexican 3.7 (2.9, 4.4) 7.1 (5.7, 8.5) 22.7 (20.6, 24.9) 6.0 (5.2, 6.8) 
Puerto-Rican 9.7 (8.1, 11.3) 4.4 (3.5, 5.2) 25.2 (23.1, 27.3) 13.3 (11.9, 14.8) 
South American 5.8 (3.9, 7.6) 6.4 (4.5, 8.2) 13.5 (11.3, 15.7) 7.0 (5.3, 8.6) 
  P <0.0001 0.01 0.003 <0.0001 
45 – 64 Males 
Dominican 9.2 (7.2, 11.2) 4.2 (3.1, 5.4) 18.3 (15.1, 21.4) 31.6 (27.4, 35.8) 
Central American 8.9 (6,8, 11.1) 4.5 (3.0, 5.9) 26.0 (22.0, 30.1) 37.0 (31.8, 42.2) 
Cuban 8.4 (6.8, 10.0) 7.4 (5.9, 8.9) 16.9 (14.5, 19.3) 41.7 (36.6, 46.8) 
Mexican 7.3 (6.2, 8.3) 4.0 (3.0, 5.0) 20.8 (18.6, 23.1) 34.7 (30.9, 38.5) 
Puerto-Rican 11.3 (9.8, 12.9) 4.2 (3.2, 5.2) 21.5 (19.1, 23.8) 33.6 (30.5, 36.7) 
South American 5.2 (3.1, 7.2) 7.3 (5.3, 9.3) 13.2 (9.7, 16.6) 31.2 (26.4, 36.0) 
  P 0.15 0.37 0.04 0.04 
≥65 Females Dominican 11.2 (7.3, 15.1) 5.7 (3.6, 7.8) 43.1 (29.7, 56.5) 72.2 (54.8, 89.6) 
3 
 
Central American 15.5 (4.0, 27.0) 1.6 (0.5, 2.7) 40.8 (30.4, 51.1) 71.7 (58.0, 85.4) 
Cuban 7.6 (5.2, 10.2) 12.2 (9.1, 15.3) 37.5 (30.4, 44.6) 70.9 (62.3, 79.6) 
Mexican 5.8 (4.2, 7.5) 6.2 (3.6, 8.9) 33.9 (27.9, 40.0) 71.0 (62.2, 79.7) 
Puerto-Rican 11.1 (8.8, 13.5) 2.4 (1.3, 3.5) 39.6 (33.2, 45.9) 64.7 (51.6, 77.8) 
South American 12.2 (7.0, 17.4) 5.2 (2.0, 8.4) 32.9 (23.5, 42.2) 63.4 (48.5, 78.3) 
  P 0.50 0.002 0.93 0.87 
≥65 Males 
Dominican 16.7 (8.8, 24.5) - 36.9 (25.0, 48.8) 73.1 (50.5, 95.7) 
Central American 10.2 (5.1, 15.3) 12.6 (2.2, 22.9) 42.6 (28.4, 56.8) 76.4 (58.6, 94.3) 
Cuban 20.1 (15.8, 24.5) 14.1 (13.4, 14.8) 34.6 (28.5, 40.8) 73.1 (61.3, 84.8) 
Mexican 16.6 (10.7, 22.5) 9.4 (8.0, 10.7) 31.6 (25.0, 38.3) 73.7 (62.1, 85.3) 
Puerto-Rican 16.2 (11.8, 20.6) 3.6 (2.0, 5.2) 44.8 (37.2, 52.5) 76.6 (65.8, 87.3) 
South American 5.5 (0.3, 10.7) 15.8 (10.3, 21.2) 28.5 (15.2, 41.8) 79.3 (60.3, 98.3) 
  P 0.71 - 0.58 >0.99 
ASCVD = atherosclerotic cardiovascular disease; LDL = low density lipoprotein 
The percentages are related to the total number of individuals eligible for statin therapy by ACC/AHA class I guidelines in each subgroup 
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Table S2. Age and Sex Stratified Prevalence estimates and 95% confidence intervals for statin therapy 
by NCEP/ATP III and 2013 ACC/AHA cholesterol treatment guidelines 
Age categories Sex Categories Ethnic Subgroups ATP III ACC/AHA 
18 – 44 Females 
Dominican 5.4 (3.8, 6.9) 9.1 (7.2, 11.1) 
Central American 6.9 (5.4, 8.3) 10.4 (8.4, 12.4) 
Cuban 4.8 (3.4, 6.1) 7.1 (5.4, 8.8) 
Mexican 6.9 (6.1, 7.7) 9.0 (8.0, 10.1) 
Puerto-Rican 8.9 (7.1, 10.8) 15.6 (13.3, 18.0) 
South American 2.4 (1.3, 3.6) 3.6 (2.1, 5.0) 
  p 0.08 0.0002 
18 – 44 Males 
Dominican 6.4 (4.5, 8.4) 8.4 (6.3, 10.6) 
Central American 4.3 (3.2, 5.4) 7.3 (5.9, 8.7) 
Cuban 5.2 (3.7, 6.6) 9.1 (7.3, 10.9) 
Mexican 9.6 (8.3, 10.9) 11.9 (10.3, 13.6) 
Puerto-Rican 7.4 (5.3, 9.5) 11.1 (9.0, 13.2) 
South American 3.2 (2.0, 4.5) 5.0 (3.6, 6.5) 
  p 0.02 0.09 
45 – 64 Females 
Dominican 23.3 (20.4, 26.2) 30.7 (27.3, 34.2) 
Central American 26.2 (23.0, 29.5) 30.8 (27.0, 34.6) 
Cuban 23.9 (20.6, 27.3) 33.4 (28.8, 38.0) 
Mexican 28.1 (25.7, 30.6) 30.7 (28.0, 33.4) 
Puerto-Rican 30.7 (28.2, 33.1) 37.8 (35.0, 40.7) 
South American 18.0 (15.2, 20.7) 24.1 (20.8, 27.4) 
  p 0.008 0.01 
45 – 64 Males 
Dominican 26.0 (20.9, 31.1) 51.3 (45.6, 57.0) 
Central American 28.9 (24.8, 33.0) 57.6 (50.9, 64.4) 
Cuban 18.6 (16.0, 21.3) 57.1 (50.0, 64.2) 
Mexican 26.5 (23.9, 29.1) 50.1 (45.2, 55.1) 
Puerto-Rican 23.0 (20.6, 25.4) 50.4 (46.5, 54.3) 
South American 16.4 (12.8, 20.1) 46.2 (40.2, 52.2) 
  p 0.006 0.14 
≥65 Females 
Dominican 52.0 (37.2, 66.8) 87.8 (68.3, 100) 
Central American 52.8 (37.5, 68.1) 88.5 (70.6, 100) 
Cuban 40.9 (33.2, 48.6) 91.4 (80.9, 100) 
Mexican 41.0 (34.6, 47.3) 82.9 (73.0, 92.8) 
Puerto-Rican 41.0 (34.6, 47.3) 78.7 (65.6, 91.9) 
South American 44.4 (38.0, 50.9) 80.6 (64.4, 96.9) 
  p 0.63 0.08 
≥65 Males 
Dominican 45.7 (32.8, 58.6) 89.8 (66.2, 100) 
Central American 43.9 (29.5, 58.2) 99.4 (78.3, 100) 
Cuban 41.0 (34.2, 48.0) 93.9 (80.5, 100) 
Mexican 41.5 (33.1, 50.0) 92.2 (78.6, 100) 
Puerto-Rican 49.9 (41.6, 58.3) 96.1 (84.4, 100) 
South American 37.4 (23.0, 51.7) 90.2 (69.0, 100) 
  p 0.87 0.58 
ASCVD = atherosclerotic cardiovascular disease; LDL = low density lipoprotein 
The percentages are related to the total number of individuals eligible for statin therapy by ACC/AHA 
class I guidelines in each subgroup 
  
5 
 
Table S3. Age and Sex Adjusted Prevalence estimates and 95% confidence intervals for statin therapy 
by NCEP/ATP III and 2013 ACC/AHA cholesterol treatment guidelines 
Ethnic Subgroups ATP III ACC/AHA 
Dominican 11.8 (10.2, 13.7) 18.7 (16.5, 21.2) 
Central American 12.1 (10.4, 14.1) 18.9 (16.7, 21.3) 
Cuban 9.3 (8.2, 10.5) 19.5 (17.7, 21.4) 
Puerto-Rican 13.1 (11.3, 15.0) 20.9 (18.2, 23.9) 
South American 7.0 (5.6, 8.8) 12.8 (10.7, 15.2) 
Mexican 13.7 (12.4, 15.1) 19.2 (17.5, 21.1) 
 
  
6 
 
Figure S1. Prevalence (%) and 95% Confidence interval of elgible Hispanic/Latinos that are 
treated with statin therapy under each guideline  
 
 
